Form 4: Alnylam CEO Greenstreet Exercises Options, Sells Shares

Alnylam Pharmaceuticals CEO Yvonne Greenstreet executed pre-planned transactions, exercising stock options and subsequently selling a portion of the acquired shares.

Summary

• Yvonne Greenstreet, CEO and Director of Alnylam Pharmaceuticals, engaged in pre-planned transactions under a Rule 10b5-1(c) trading plan adopted on August 13, 2025.
• On November 12, 2025, Greenstreet exercised options to acquire 650 shares of common stock at $42.22 and 15,000 shares at $119.13.
• On November 13, 2025, Greenstreet exercised options to acquire an additional 10,000 shares of common stock at $119.13.
• Concurrently, on November 12, 2025, Greenstreet sold a total of 12,270 shares of common stock at weighted average prices ranging from $448.07 to $458.42.
• On November 13, 2025, Greenstreet sold an additional 9,790 shares of common stock at weighted average prices ranging from $447.73 to $454.69.
• Following these transactions, Greenstreet directly owns 65,409 shares of Alnylam common stock and indirectly owns 407 shares through a managed 401(k) account.
• The transactions resulted in a net decrease of 650 shares in direct beneficial ownership from the initial reported amount after the first acquisition.

Sentiment

Score: 4

Explanation: While the transactions were pre-planned under a 10b5-1 plan and involved exercising options at significantly lower prices, the net disposition of a substantial number of shares by a key executive could be viewed with slight caution by investors, even if it's for personal financial planning.

Positives

• Exercising stock options indicates a realization of value from previously granted equity incentives.
• The exercise prices of $42.22 and $119.13 are significantly lower than the sale prices, indicating substantial gains for the reporting person.
• Transactions were conducted under a Rule 10b5-1(c) plan, suggesting pre-planned activity rather than a reaction to immediate market events.
• Acquisition of 407 shares indirectly through the 401(k) plan shows continued participation in company benefits.

Negatives

• A significant number of shares (22,060) were sold by a key executive, which could be interpreted as a reduction in direct exposure to the company's future performance.
• The net effect of the reported transactions was a decrease of 650 shares in direct beneficial ownership.

Related Party Transactions

• Acquisition of 407 shares of ALNY common stock by the Reporting Person under the issuer's 401(k) plan as a result of the issuer's 401(k) matching contribution program.

Stakeholder Impact

• Shareholders may view the net selling by the CEO as a signal, although the pre-planned nature mitigates immediate concerns about company performance.

Key Dates

Recommendation

The filing details pre-planned insider transactions, including the exercise of options and subsequent sale of shares by the CEO. While the sales represent a reduction in direct ownership, they were executed under a Rule 10b5-1 plan, indicating a pre-determined financial strategy rather than a reaction to new negative information. The significant gains realized from option exercises are positive for the executive. Given the nature of a Form 4, which is a disclosure of personal trading activity rather than a company performance update, a 'hold' recommendation is appropriate, advising investors to maintain their current position while monitoring future company performance and broader market trends.

Keywords

Alnylam Pharmaceuticals, ALNY, Yvonne Greenstreet, Insider Trading, SEC Form 4, Stock Options, Share Sale, Executive Compensation, Rule 10b5-1, Biotechnology, Pharmaceuticals